丙型肝炎治疗候选者的精神疾病管理
Management of Psychiatric Disease in Hepatitis C Treatment Candidates.
作者信息
Lotrich Francis
机构信息
Department of Psychiatry, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, USA.
出版信息
Curr Hepat Rep. 2010 Apr 6;9(2):113-118. doi: 10.1007/s11901-010-0035-5.
Abstract
Depression and other influences on mental health can impact antiviral response rates during chronic hepatitis C treatment, the quality of life for these patients, and the risk for adverse outcomes such as suicide. Enhanced treatment outcomes for patients who are receiving interferon-α requires 1) addressing preexisting mental health problems, 2) alleviating psychiatric conditions that emerge during treatment, and 3) prediction and prevention of these conditions. Accumulating evidence indicates that these three goals are feasible. Collaborative involvement of psychiatric management may often be critical in this regard.
摘要
抑郁症及其他对心理健康的影响，会在慢性丙型肝炎治疗期间影响抗病毒反应率、这些患者的生活质量以及诸如自杀等不良后果的风险。提高接受α-干扰素治疗患者的治疗效果需要：1）解决已有的心理健康问题；2）缓解治疗期间出现的精神状况；3）预测和预防这些状况。越来越多的证据表明这三个目标是可行的。在这方面，精神科管理的协作参与往往至关重要。
相似文献
1
Management of Psychiatric Disease in Hepatitis C Treatment Candidates.
Curr Hepat Rep. 2010 Apr 6;9(2):113-118. doi: 10.1007/s11901-010-0035-5.
2
Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.
J Hepatol. 2012 Dec;57(6):1379-90. doi: 10.1016/j.jhep.2012.07.037. Epub 2012 Aug 7.
3
Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.
Gastroenterol Clin North Am. 2004 Mar;33(1 Suppl):S35-50. doi: 10.1016/j.gtc.2003.12.005.
4
[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
Encephale. 2005 May-Jun;31(3):349-57. doi: 10.1016/s0013-7006(05)82400-5.
5
Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
Int J Clin Pharm. 2015 Dec;37(6):1143-51. doi: 10.1007/s11096-015-0177-1. Epub 2015 Aug 13.
6
[Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients].
Encephale. 2003 Jul-Aug;29(4 Pt 1):362-5.
7
Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
Antivir Ther. 2010;15(4):599-606. doi: 10.3851/IMP1566.
8
Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
Aliment Pharmacol Ther. 2009 Nov 15;30(10):1049-59. doi: 10.1111/j.1365-2036.2009.04123.x. Epub 2009 Aug 18.
9
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Cochrane Database Syst Rev. 2014 Jun 17;2014(6):CD011132. doi: 10.1002/14651858.CD011132.pub2.
10
Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
J Clin Gastroenterol. 2007 Mar;41(3):322-8. doi: 10.1097/01.mcg.0000225629.22286.96.
引用本文的文献
1
Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
World J Gastroenterol. 2023 Jul 7;29(25):4085-4098. doi: 10.3748/wjg.v29.i25.4085.
2
Double blind, randomised trial to compare efficacy of escitalopram versus citalopram for interferon induced depression in hepatitis C patients.
Contemp Clin Trials Commun. 2020 Jul 19;19:100622. doi: 10.1016/j.conctc.2020.100622. eCollection 2020 Sep.
3
The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study.
PLoS One. 2016 Feb 22;11(2):e0148596. doi: 10.1371/journal.pone.0148596. eCollection 2016.
4
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.
Neuroscience. 2013 Aug 29;246:199-229. doi: 10.1016/j.neuroscience.2013.04.060. Epub 2013 May 3.
5
Hepatitis C: management of side effects in the era of direct-acting antivirals.
Curr Gastroenterol Rep. 2013 Jan;15(1):305. doi: 10.1007/s11894-012-0305-1.
本文引用的文献
1
Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment.
Psychiatry Res. 2010 May 15;177(1-2):240-5. doi: 10.1016/j.psychres.2009.02.011. Epub 2010 Apr 9.
2
Major depression during interferon-alpha treatment: vulnerability and prevention.
Dialogues Clin Neurosci. 2009;11(4):417-25. doi: 10.31887/DCNS.2009.11.4/felotrich.
3
Managing depression during hepatitis C treatment.
Can J Psychiatry. 2009 Sep;54(9):614-25. doi: 10.1177/070674370905400906.
4
Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.
Brain Behav Immun. 2009 Nov;23(8):1109-16. doi: 10.1016/j.bbi.2009.07.001. Epub 2009 Jul 15.
5
Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.
Biol Psychiatry. 2009 Feb 15;65(4):344-8. doi: 10.1016/j.biopsych.2008.08.009. Epub 2008 Sep 18.
6
Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.
Biol Psychiatry. 2009 Feb 15;65(4):296-303. doi: 10.1016/j.biopsych.2008.08.010. Epub 2008 Sep 18.
7
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.
Mol Psychiatry. 2009 Dec;14(12):1095-104. doi: 10.1038/mp.2008.48. Epub 2008 May 6.
8
High frequency of unrecognized mental disorders in HCV-infected patients.
Gen Hosp Psychiatry. 2008 Jan-Feb;30(1):80-2. doi: 10.1016/j.genhosppsych.2007.08.014.
9
Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
J Clin Gastroenterol. 2008 Jan;42(1):92-6. doi: 10.1097/01.mcg.0000225645.75651.b8.
10
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
Gut. 2008 Apr;57(4):531-6. doi: 10.1136/gut.2007.131607. Epub 2007 Dec 13.
Zotero 插件